JAGX Jaguar Health, Inc.

NASDAQ
$0.39

Jaguar Health, Inc. Q3 F2026 Earnings Call Transcript

AI Conference Call Analysis

Sign in or subscribe to read.
Sherry
Conference Call Operator
Good morning. Before I turn the call over to management, I would like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, product initiatives, including products in the development stage which may not achieve scientific objectives or meet stringent regulatory requirements. forward looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward looking statements. These statements are based on currently available information and management's current assumptions, expectations, and projections of future events. While management believes its assumptions, expectations, and projections are reasonable in the view of currently available information, Your question not to place undue reliance on these forward-looking statements. The company's actual results may differ materially from those discussed during this webcast for a variety of reasons, including those described in the forward-looking statements and refactor section of the company's 10-K form for the year 2025, which was filed with the SEC on April 7, 2026. It's other filings with the SEC which are available on the investor relations section of Jaguar's website. Except as required by law, Jaguar undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events, or otherwise. Additionally, please note that the company supplements its condensed consolidated financial statements presented on a GAAP basis Thank you for joining us. and are not substitutes for or superior to measures of financial performance in conformity with GAAP. Today's conference is being recorded. At this time, it is my pleasure to turn the call over to Lisa Conte, Jaguars Health founder, president and chief executive officer. Lisa, the floor is yours.
Lisa Conte
Founder, President and Chief Executive Officer, Jaguar Health
Thank you, Sherry. And thank you, everybody, for joining the Investor Webcast today. As you heard, my name is Lisa Conte. I'm the founder, president, and CEO of Jaguar Health and our wholly owned subsidiary, NAPO Pharmaceuticals. I am also the chairman of our Italian subsidiary, NAPO Therapeutics. And as usual, I may use the words Jaguar and NAPO interchangeably when I'm referring to the company. After I speak today, our CFO, Carol Lizak, will provide a recap of the financial highlights for the third quarter of 2026. One key highlight that I want to highlight Jaguar significantly reduced its outstanding debt balance by over $10 million in the third quarter of 2026. The signing of a U.S. commercial out-license agreement with FuturePAC for MyTessy, the brand name of our FDA-approved formulation of crofilomer for adults living with HIV, AIDS, and diarrhea. Included in that license also was Canalivia CA-1, our conditionally FDA-approved formulation of crofilomer for doggies with chemotherapy-induced diarrhea. We made this strategic decision to outlicense Mitessi to FuturePAC first because they had recently acquired Thera Technologies, an HIV-focused commercial company with more than four times the commercial effort of Jaguar in the United States. The HIV space and they are focused completely in the U.S. HIV space and they have other HIV-related products. Secondly, this fulfilled our strategic plan to bring in meaningful, non-dilutive dollars to help fund our sharp development focus on our late-stage clinical development program for a novel, proprietary, powder for oral solution formulation of CROFELIMER. Significance of the novel formulation is that this is a different product, a whole different business structure of CROFELIMER, specifically for rare intestinal failure indications. Same active ingredient, same product, certain manufacturing activities are common to Mitessi, yet a different formulation for the rare intestinal failure indications. Rare, meaning we have orphan drug designation for the intestinal failure indications, two different indications in both the United States and Europe. Well, Jaguar, NAPO remains the manufacturer of Mitessi and Canalevia CA1, therefore supplying the product to FuturePAC at a cost plus term, so a profit center there. We are now fully a rare disease GI company with 100% of our human development efforts sharply and strategically focused on this rare disease program. For many years prior to the Outlicense Agreement With FuturePAC, we were selling Mitessi ultimately into the distributors and had a sales force promoting directly to the physicians who are prescribing Mitessi to patients and the expense associated with that and the expense associated with a single product as opposed to the Theratex situation right now. At this point, we are operating as a supplier of Mitessi to FuturePAC. and therefore a much different impact on the reporting of sales and the revenue numbers that we are reporting, but a different impact on the non-diluted dollars that we receive from that agreement.
Carol Lizak
Chief Financial Officer, Jaguar Health
So back to our main strategic focus.
Lisa Conte
Founder, President and Chief Executive Officer, Jaguar Health
Our ultimate strategy continues to involve evaluating strategic alternatives driven by the tremendous value to potential development and a commercialization partner for our rare disease intestinal failure program. for our late-stage rare disease intestinal failure program. Just to put this in perspective, the Outlicensed to Future PAC was $18 million up front, primarily for the US HIV market, a market with a peak annual market opportunity of maybe $50 to $70 million annually. The global market for short bowel syndrome, which includes short bowel syndrome with intestinal failure, as well as some rare congenital disorders, is estimated to reach more than $8 billion in 2033, according to third-party market research. A different third-party market research estimates the value of just the global MVID marketplace, which is an ultra-rare indication for which there are no treatments, nothing in clinical development. They put that estimate at over $2 billion by 2032. Our strategic goal is to, again, bring in non-dilutive dollars from a strategic partner, as we did with FuturePak for Mitessi. Market differences are in the tens of millions for Mitessi for HIV, United States, versus billions for intestinal failure globally.
Carol Lizak
Chief Financial Officer, Jaguar Health
I just referred to MVID.
Lisa Conte
Founder, President and Chief Executive Officer, Jaguar Health
It's Pediatric Microvelous Inclusion Disease, As I mentioned, an ultra-rare disorder, no approved therapies, a lethal natural history. This is Jaguar's very near-term value driver in the intestinal failure program. It's our lead target indication. We have completed enrollment in a pivotal trial, a blinded pivotal trial, to support a targeted new drug application submission in mid-2027. We're talking like eight, nine months away. This is very exciting, meaningful to MVID patients and the catastrophic impact to their health and to the impact on their family and other supportive caregivers, of which there are many for MVID patients. As awareness in prophylamers impact grows with respect to our compassionate use patients, which has been published and presented at various medical conferences, we've experienced and many patient and physician inquiries for future possibility for access to profilamer. Short bowel syndrome, which you'll hear me refer to as SBS or SBSIS, short bowel syndrome with intestinal failure, represents a larger follow-on indication using the same dosage formulation and the same physiological mechanism for intestinal failure as with MVID patients. and MVID are both separate rare disease orphan designations each in the US and Europe. Our intestinal failure program represents a blockbuster global market opportunity. First and foremost in terms of addressing the catastrophic unmet medical need in patients, blockbuster in terms of the beneficial impact to morbidity and mortality and the cost to the healthcare system. and then also the financial return opportunity for all stakeholders, including our shareholders. And this return opportunity, of course, is especially important to the motivation and the incentive to potential corporate partners and strategic alternatives that we are looking at. As I mentioned, the global market for SPSIF is estimated at over $8 billion, again by a third party in 2000 33, and VID over $2 billion. So I want to take a moment to describe not just dollars, but the catastrophic impact of intestinal failure on patients and what this means for their caregiving community, which includes family members, healthcare professionals, nurses, nutritionists, others. It does take a village to manage these situations. Intestinal failure It's a debilitating condition that often requires patients to receive life-sustaining fluids, electrolytes, IV, IV administration for the nutrients of life, which is all encompassed in something called TPN, total parenteral nutrition. Total parenteral nutrition with supplemental fluids is called parental support. This is IV nutritional support, IV nutritional support. Many intestinal failure patients require this parenteral support up to 20 hours a day, seven days a week. IV nutrition. So obviously this is a catastrophic situation for the patient, both from a healthcare standpoint and the obvious impact on quality of life. Parenteral support is supportive. It's necessary for life. It's sustenance. Yet it's associated with quite serious complications, including liver and kidney toxicities, compromised cognitive functioning, negative impact on growth, infections, line infections from being on IV nutrition, and ultimately not just the morbidity aspects of all that, but mortality as well. This is why standard of care parental support, TPN, is referred to as lethal natural history for these patients. And the cost is meaningful. It's estimated at about $500,000 a year in the United States per patient. And the cost to the healthcare system is inevitably higher, can top a million dollars per year per patient due to the complications of infections and keeping that balance of nutrients of life correct. and this is all on top of the mortality risk. MVID is a congenital disease. So the patient, the infant, the baby is born and has massive diarrhea and is unable to absorb nutrients of life. If the baby is not diagnosed immediately, the newborn, they often die right away. If the newborn is diagnosed, they will be on parental support for the rest of their life. up to seven days a week, 20 hours a day. The key of what we're looking for in providing adjunctive therapy to these patients is a reduction in the amount of time they are on parental support. Parental support is life-sustaining, but can we reduce the amount of time that they're on parental support and therefore have a significant impact on the massive toxicities and comorbidities are life shortening for these patients and in this case for these infants. Even a reduction of 5% to 10% is considered clinically meaningful. Remember, these are infants enabling the baby to grow to a child and thrive is life and disease altering and altering for the family condition as well. So, The endpoint in the prophylomeric clinical development program is, in fact, the reduction in parenteral support. Let's say even 10% to 15%. That would allow the patient to receive a significant percentage of their parenteral support at night while sleeping, preserving some quality of life, the ability to go to school during waking hours. The patient would not need to be attached to an IV to go through some of their normal activities of Daily Living, and that, of course, reduces the situation and the environment and the circumstances for infection as well. Keeping in mind that number of 5, 10, 15% is meaningful, this past June we presented groundbreaking results at the 58th Annual European Society for Pediatric Gastroenterology and Pathology and Nutrition meeting. This was in Lille, France. It's referred to as FSCAM. In that presentation, in an MVID patient, The weekly parental support requirements normalized to body weight were reduced by up to 48%. Remember, 10 to 15 is considered clinically meaningful. 48% following more than 12 months of profilamere therapy with no safety issues. We also presented to short bowel syndrome IF pediatric patients and the PS requirements were reduced by up to 40% again for over a year of treatment with no safety issues. These results are stunning. It's hard to express. It's hard to communicate how clinically relevant this is and how rewarding it is for all involved to see these patients, these children that are thriving and why there is so much awareness growing in the intestinal failure community. Thank you for joining us. in providing the product for that. There have been no profilamer-related safety issues in our intestinal failure patients in any patient that we've treated with anything. And this is very consistent with profilamer in thousands of patients that have been in clinical trials or have accessed the product that is now commercialized. A hallmark of profilamer is this safety profile and we should never take it for granted because one of the most common reasons why new drug applications fail is because of a safety issue. As a reminder, drugs are approved by the FDA. New drug applications are approved by the FDA on their benefit-risk ratio. When the risk is zero, the benefit exists into perpetuity. So again, in the program, in addition to these compassionate use programs or expanded access, they have different names. that we have presented. Additionally, we've completed enrollment in a blinded clinical trial for MVID. The trial is taking place at clinical sites in the United States, Italy, and the UAE, Emirates, in Dubai and Abu Dhabi. In support of our planned new drug application filing in patients in this trial, we submitted an amendment and we did receive FDA authorization for a treatment-only extension phase of the trial after the placebo phase of the trial. This was announced this past September. All, all of the randomized pediatric MVID patients in this trial have entered the single-blind extension phase, are receiving crofilomer at this time. This is the powder for oral solution, and this is as adjunctive therapy to their parental support, allows the patients to benefit from the product and allows us to collect additional safety information, very important for a new drug application, as well as continued efficacy. With the data from the patients in this extension and the early access compassionate use patients that I previously discussed where the data has been presented, we're talking about the opportunity for the new drug application for MVID. This Ultra Rare Disease, mid-2027, with essentially 3% to 4% of the patient population, which is a typical percentage of treatment across almost any indication in clinical trial, pivotal drug trials. And for us, this is literally a single digit number of patients and shows the efficiency of orphan drug indications and ultra rare indications. Also in 2027, we plan to submit an application for breakthrough therapy designation from the FDA for profilamer or MVID in the United States. If we achieve such designation from the FDA, this gives us the opportunity for review upon filing the new drug application of perhaps just four months, which could make the product approval in the end of 2027 possible. Now I'm going to move to the adult patient program. And last month at the American College of Gastroenterology annual scientific meeting, we presented or positive preliminary results were presented by an investigator for the ongoing open-label third-party pilot study of crofilomer. Again, the same powder for oral solution in adult patients with type 1 short bowel syndrome with intestinal failure. Intestinal failure in short bowel syndrome is the same clinical situation as intestinal failure in MVID children. Short bowel syndrome patients are unable to absorb the nutrients of life because they literally have a short bowel. There's not enough surface area. A normal intestine is about 20 to 25 feet. An SPSIF intestine may be 5 feet or less. So they, too, end up on parental support, again, up to 20 hours a day, seven days a week, with the same comorbidities associated with that TPN parental support, the same catastrophic toxicities that I have previously described in the MVID patients. It's because of the TPN and the parental support. Additionally, we have ongoing right now a Phase II randomized assessment double-blind placebo-controlled trial with this formulation of crofilomer, the same one that's in MVID, at various sites in Germany and Italy for SBSIF in adult patients. SBSIF is still an orphan indication, though a larger patient population of MVID. MVID arises from congenital abnormalities. SBS can also result from congenital abnormalities, yet also Thank you for joining us. That's for MVID is targeted mid-2027, as I mentioned. And we expect this filing to be coincident with the timing of the availability of the results, the unblinding of the results from the Phase II study with short bowel syndrome in adults. MVID is an important stepping stone to our planned pathway for ultimate approval of profilamer for SPS. Important and crucial first and foremost for patient benefit and access for MVID for those babies, but also for the company's strategy to enter a blockbuster indication with no alternative treatments, dramatic unmet medical need. The safety data for MVID and SBS would be the same. Manufacturing, it's the same. Formulation would be the same. So the two most common reasons why new drug applications fail would be addressed by this first approval for MVID, potential approval for MVID, again, the stepping stone into SBS. From a standpoint of competition, there's nothing out there for MVID. There's nothing out there in development. There's nothing for these patients beyond parenteral support. And this, of course, would be adjunctive therapy to the life-sustaining therapy. Thank you for joining us. Again, we far exceeded that reduction with the 40% to 45% in both the MVID and the short bowel syndrome compassionate use expanded access patients that have already been reported. GLP-2 growth hormone for SPS is not standard of care. It's utilized in like 5% to 7% of the patients. There's many, many side effects. And it's a growth hormone. You can't use a growth hormone, for example, Thank you for joining us. with a clinical benefit of about 10% to 15% reduction in parental support. Provelomer, on the other hand, we are seeking to have that become standard of care for intestinal failure first in MVID, then in SBSIF, and there's many other intestinal failure, TPN, PS-dependent patient populations in the future. With the clinical proof of concept data we have in hand and the very, very near-term clinical and regulatory milestones ongoing, we're confident in our ability to execute our business development goals in our intestinal failure program and further our program and our strategy and how we have executed in the past to bring in serious, meaningful, valuable, non-dilutive dollars commensurate with the market size, addressing the serious unmet medical need driven first and foremost by the benefit and the benefit risk with the risk being nearly zero that providing to patients with no alternative treatment and all the business benefits that come from that as well. I should mention the major focus of our business overwhelmingly is human health and of course the Rare Disease Program is 100% of that human focus. Yet we do have a small business, small business in animal health. And we are pleased to announce recently that Neonorm Dog, that's the product name, Neonorm Dog is now available from Amazon. We expect it to be available fairly soon from other animal health channels with great access. And it's an absolutely fantastic opportunity for pet owners and veterinarians to access animal health products. Neonorm Dog is an extension of Jaguar's non-prescription Neonorm franchise. So it's an extension into companion animals. Neonorm franchise currently includes Neonorm for foals, horses, foals, and calves. It's a plant-based product to support proper hydration and bowel health in pre-weaned foals and calves. Neonorm Doggy is access to a plant-based non-prescription product to support normal stool consistency and GI fluid balance in dogs. With Neonorm Dog in particular, we're leveraging the relationships that we, Jaguar, built over the years when we were promoting and educating around Canolevia CA1, our prescription product for chemotherapy-induced diarrhea in dogs, which now is licensed and promoted and educated by FuturePak. The Neonorm Franchise. So I'll actually conclude at that point. With this overview, you can hear we're very excited, very enthused, very busy, very focused with what we're doing, in particular with the IF program. I'm going to hand the discussion now over to Carol Lizak, our CFO, and let her give a recap of the financial highlights, including the very, very meaningful and important reduction in debt that we achieved in the third quarter of this year. Carol, on to you.
Carol Lizak
Chief Financial Officer, Jaguar Health
Well, thank you, Lisa, and thank you to all of you who have joined our webcast today. I'll begin my review of our financials for the third quarter of 2026. As Lisa mentioned, Jaguar entered into a U.S. commercial licensing agreement in January 2026 with FuturePAC. Jaguar remains the manufacturer of Mitessi and Canalivia CA-1, supplying the products to FuturePak at cost plus terms, and now operates as a distribution entity for Mitessi and Canalivia CA-1 with a primary focus on research and development efforts related to the company's late stage development program for its Powder for Oral Solution Formulation of Cofelomer for Rare Disease Indications Related to Intestinal Failure in Humans. As announced in August 2026, Jaguar satisfied the closing conditions required to receive payment of the non-dilutive approximately $1.8 million holdback amount of the upfront fee from FuturePak. Additionally, the company recognized license fees of $42,000 in the third quarter of 2026 from a securities purchase agreement with a European partner, which was supported by a binding term sheet. As of September 30, 2026, the total deferred revenue associated with this contract amounted to $425,000. There was no federal grant revenue recognized in the third quarter of 2026 for the clinical study related to the treatment of chemotherapy-induced diarrhea in dogs, and $25,520 in the month period ended September 30, 2026. The total net revenue for the company's prescription products was approximately and many more. Thank you. Future Pack is privately held and does not report Mitessi sales. The total net revenue for the company's prescription products in the second quarter of 2026 was approximately $1.2 million. Compared to the third quarter of 2025, the number of Mitessi bottles the company sold in the third quarter of this year increased significantly and but commercial costs were substantially decreased. Prescription products net revenue in the third quarter of last year when the company had a sales force and was focused on commercial sales of Mitessi was approximately $3 million. The loss from operations decreased by 1.2 million going from a loss of 7.2 million in the quarter ended September 30, 2025 to a loss of 6 million in the third quarter ended September 30, 2026. This change was primarily due to a 700,000 decrease in total net revenue, which was offset by a reduction in operating expenses of approximately $2 million. attributed to the future PAC licensing agreement. Net loss decreased by approximately 3.8 million from a loss of 9.6 million in the quarter ended September 30, 2025 to a loss of 5.8 million in the quarter ended September 30 this year. In addition to the loss from operations, Interest expense increased by $150,000 from $6,000 of interest income for the quarter ended September 30, 2025 to $156,000 in the quarter ended September 30 this year due to interest expenses accrued on notes. The fair value of financial and hybrid instrument designation at fair value option or what we call FBO decreased by about $2.2 million from a loss of 2.3 million in the quarter ended September 30, 2025 to a loss of $96,000 in the same period in 2026. This is primarily due to lower outstanding carrying amounts of royalty interests and notes payable designated at FVO relative to their fair values resulting in lower fair value changes during the period. Gain on extinguishment of debt increased by 600,000 from zero in the three months ended September 30, 2025. The increase was primarily attributable to the extinguishment of the street of the note following the company's exchange transaction in which the company issued shares of its common stock to Streeterville resulting in the full repayment and cancellation of the Streeterville new note. And finally, non-GAAP recurring EBITDA for the third quarters of 2026 and 2025 were a net loss of approximately $5 million and $9 million, respectively. So that concludes my recap of high-level financials for the third quarter of 2026. I will now hand the discussion back to Lisa. Thank you.
Lisa Conte
Founder, President and Chief Executive Officer, Jaguar Health
Thanks, Carol. Okay, strategically expect business updates in the near future as we continue to evaluate business development and other strategic alternatives driven by the ongoing and very near-term catalysts in our rare disease program. This concludes our webcast for today. Thank you very much for joining. Thank you very much for those who have followed us for some time. I wish you all a wonderful, those in the United States, wonderful Thanksgiving holiday with your families, and we'll see you next quarter. Bye-bye.
Sherry
Conference Call Operator
Thank you. This concludes our webcast. You may disconnect at this time.